Assessment of novel iloperidone- and idebenone-loaded nanostructured lipid carriers: brain targeting efficiency and neuroprotective potential.
To evaluate the outcome of combining iloperidone with idebenone in the form of brain-targeted nanostructured lipid carrier (NLC) on the expression of endogenous antioxidant enzymes present in the brain, and hence establish the neuroprotective activity. The combination NLC demonstrated good targeting potential (>85%) as compared with pure iloperidone (22.21%). The levels of various endogenous antioxidant enzymes present in the brain were reduced significantly (p < 0.001) in case of 28 days repeated administration of pure iloperidone, while administration of the combination NLC helped to restore the levels of these enzymes. Combining iloperidone with idebenone and converting into NLC has contributed in effectively reducing oxidative stress in the brain and helped in reversing the catalepsy induced by repeated iloperidone administration.